Long-term Visual Outcomes of Intravitreal Bevacizumab in Inflammatory Ocular Neovascularization

American Journal of Ophthalmology

Volumn 148, Issue 2, 2009, Pages

  Mansour, Ahmad M ^a,b   Arevalo, J Fernando ^c   Ziemssen, Focke ^d   Mehio Sibai, Abla ^a   Mackensen, Friederike ^e   Adan, Alfredo ^f   Chan, Wai Man ^g   Ness, Thomas ^h   Banker, Alay S ⁱ   Dodwell, David ^j   Chau Tran, Thi Ha ^k   Fardeau, Christine ^k   LeHoang, Phuc ^k   Mahendradas, Padmamalini ^l   Berrocal, Maria ^m   Tabbarah, Zuheir ^a,b   Hrisomalos, Nicholas ⁿ   Hrisomalos, Frank ⁿ   Al Salem, Khalil ^a   Guthoff, Rainer ^o  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b RAFIC HARIRI UNIVERSITY HOSPITAL   (Lebanon)

^c UNIVERSIDAD DE LOS ANDES   (Venezuela)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY OF BARCELONA   (Spain)

^g CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ Laser Centre   (India)

^j Springfield Eye Clinic   (United States)

^k PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^l Narayana Health City   (India)

^m UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

ⁿ INDIANA UNIVERSITY   (United States)

^o UNIVERSITY OF WÜRZBURG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; ARTICLE; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; EYE NEOVASCULARIZATION; FEMALE; FOLLOW UP; HUMAN; INFLAMMATORY DISEASE; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OCULAR FIBROSIS; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA FOVEA; RETINA MACULA HEMORRHAGE; RETROSPECTIVE STUDY; THICKNESS; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 67650427145     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2009.03.023     Document Type: Article

References (31)

1. Perentes Y., van Tran T., Sickenberg M., and Herbort C.P. Subretinal neovascular membranes complicating uveitis: frequency, treatments, and visual outcome. Ocul Immunol Inflamm 13 (2005) 219-224
2. Machida S., Fujiwara T., Murai K., Kubo M., and Kurosaka D. Idiopathic choroidal neovascularization as an early manifestation of inflammatory chorioretinal diseases. Retina 28 (2008) 703-710
3. Mansour A.M., Mackensen F., Arevalo J.F., et al. Intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol 146 (2008) 410-416
4. Cantrill H.L., and Folk J.C. Multifocal choroiditis associated with progressive subretinal fibrosis. Am J Ophthalmol 101 (1986) 170-180
5. Palestine A.G., Nussenblatt R.B., Parver L.M., and Knox D.L. Progressive subretinal fibrosis and uveitis. Br J Ophthalmol 68 (1984) 667-673
6. Ziemssen F., Deuter C.M., Stuebiger N., and Zierhut M. Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin). Graefes Arch Clin Exp Ophthalmol 245 (2007) 917-918
7. Cordero Coma M., Sobrin L., Onal S., Christen W., and Foster C.S. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 114 (2007) 1574-1579
8. Mackensen F., Heinz C., Becker M.D., and Heiligenhaus A. Intravitreal bevacizumab (Avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina 28 (2008) 41-45
9. Kleiner R.C., Ratner C.M., Enger C., and Fine S.L. Subfoveal neovascularization in the ocular histoplasmosis syndrome. A natural history study. Retina 8 (1988) 225-229
10. Brown Jr. J., Folk J.C., Reddy C.V., and Kimura A.E. Visual prognosis of multifocal choroiditis, punctate inner choroidopathy, and the diffuse subretinal fibrosis syndrome. Ophthalmology 103 (1996) 1100-1105
11. Yang P., Ren Y., Li B., Fang W., Meng Q., and Kijlstra A. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. Ophthalmology 114 (2007) 606-614
12. Rosenfeld P.J., Saperstein D.A., Bressler N.M., et al. ; Verteporfin in Ocular Histoplasmosis Study Group. Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled, open-label 2-year study. Ophthalmology 111 (2004) 1725-1733
13. Wachtlin J., Heimann H., Behme T., and Foerster M.H. Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases. Graefes Arch Clin Exp Ophthalmol 241 (2003) 899-906
14. Parodi M.B., Di Crecchio L., Lanzetta P., Polito A., Bandello F., and Ravalico G. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization associated with multifocal choroiditis. Am J Ophthalmol 138 (2004) 263-269
15. Nowilaty S.R., and Bouhaimed M. Photodynamic Therapy Study Group. Photodynamic therapy for subfoveal choroidal neovascularization in Vogt-Koyanagi-Harada disease. Br J Ophthalmol 90 (2006) 982-986
16. Mauget-Faysse M., Mimoun G., Ruiz-Moreno J.M., et al. Verteporfin photodynamic therapy for choroidal neovascularization associated with toxoplasmic retinochoroiditis. Retina 26 (2006) 396-403
17. Chan W.M., Lai T.Y., Liu D.T., and Lam D.S. Intravitreal bevacizumab (Avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol 143 (2007) 977-983
18. Adán A., Navarro M., Casaroli-Marano R.P., Ortiz S., and Molina J.J. Intravitreal bevacizumab as initial treatment for choroidal neovascularization associated with presumed ocular histoplasmosis syndrome. Graefes Arch Clin Exp Ophthalmol 245 (2007) 1873-1875
19. Schadlu R., Blinder K.J., Shah G.K., et al. Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis. Am J Ophthalmol 145 (2008) 875-878
20. Adán A., Mateo C., Navarro R., Bitrian E., and Casaroli-Marano R.P. Intravitreal bevacizumab (Avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina 27 (2007) 1180-1186
21. Ben Yahia S., Carl P., Herbort C.P., et al. Intravitreal bevacizumab (Avastin) as primary and rescue treatment for choroidal neovascularization secondary to ocular toxoplasmosis. Int Ophthalmol 28 (2008) 311-316
22. Kurup S., Lew J., Byrnes G., et al. Therapeutic efficacy of intravitreal bevacizumab on posterior uveitis complicated by neovascularization. Acta Ophthalmol (2008) Forthcoming
23. Küçükerdönmez C., Akova Y.A., and Yilmaz G. Intravitreal injection of bevacizumab in Eales disease. Ocul Immunol Inflamm 16 (2008) 63-65
24. Kumar A., and Sinha S. Rapid regression of disc and retinal neovascularization in a case of Eales disease after intravitreal bevacizumab. Can J Ophthalmol 42 (2007) 335-336
25. Perentes Y., Chan C.C., Bovey E., et al. Massive vascular endothelium growth factor (VEGF) expression in Eales' disease. Klin Monatsbl Augenheilkd 219 (2002) 311-314
26. Murugeswari P., Shukla D., Rajendran A., et al. Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and Eales' disease. Retina 28 (2008) 817-824
27. Maruotti N., Cantatore F.P., Nico B., et al. Angiogenesis in vasculitides. Clin Exp Rheumatol 26 (2008) 476-483
28. Shimada H., Yuzawa M., Hirose T., et al. Pathological findings of multifocal choroiditis with panuveitis and punctate inner choroidopathy. Jpn J Ophthalmol 52 (2008) 282-288
29. Tran T.H., Fardeau C., Terrada C., et al. Intravitreal bevacizumab for refractory choroidal neovascularization (CNV) secondary to uveitis. Graefes Arch Clin Exp Ophthalmol 246 (2008) 1685-1692
30. Chang L.K., Spaide R.F., Brue C., et al. Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration. Arch Ophthalmol 126 (2008) 941-945
31. Fine H.F., Zhitomirsky I., Freund K.B., et al. Bevacizumab (Avastin) and ranibizumab (Lucentis) for choroidal neovascularization in multifocal choroiditis. Retina 29 (2009) 8-12